Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this retrospective study, 75% of patients with alopecia areata responded well to an 8-week oral methylprednisolone tapering treatment, but 28.4% relapsed within an average of 5.5 months; young age and extensive alopecia predicted poorer responses, and low vitamin D was linked to relapse.

This study found that Diphenylcyclopropenone (DCP) was effective for treating extensive alopecia areata in Thai patients, although a high relapse rate suggests maintenance therapy might be necessary.

This case report describes a non-thymoma-associated exfoliative dermatitis in an 8-year-old cat, where treatment with cyclosporine A alongside prednisolone and antibiotics resolved skin lesions without relapse after an initial recurrence.

This study found that in alopecia areata, treatment with the oral JAK-inhibitor tofacitinib decreased clonally expanded CD8⁺ T cells in the scalp, but many expanded clones did not completely disappear, potentially leading to relapse after stopping treatment.

This study found that using methotrexate with corticosteroids may support hair regrowth in severe alopecia areata, but adverse effects and relapses were common, suggesting more controlled trials are needed.

This study found that while both microneedling-assisted methotrexate and triamcinolone acetonide treatments led to improvements in recalcitrant alopecia areata, methotrexate-treated areas had significantly better outcomes in terms of SALT score reduction, patient satisfaction, and relapse rates, suggesting its superior short-term efficacy.

This review reports that Janus kinase inhibitors and regenerative therapies, such as exosomes and platelet-rich plasma, significantly improve scalp hair regrowth in moderate-to-severe alopecia areata, though challenges like high relapse rates and socioeconomic barriers remain, underscoring the need for personalized treatment protocols.

In this case report, a 7-year-old girl with alopecia areata showed approximately 80% hair regrowth and resolved scalp symptoms after four months of individualized homeopathic treatment, maintaining clinical improvement with minimal relapse over more than a year.

In this case study, a woman with alopecia areata experienced significant hair regrowth after starting ritlecitinib but developed an acneiform eruption, leading to the discontinuation of the drug and subsequent hair loss relapse; the eruption suggests a treatment-limiting adverse effect of JAK inhibitors.

This study found that individualized homeopathic medicine can significantly improve outcomes in patients with alopecia areata, including complete hair regrowth and reduced SALT scores within 5 to 12 months, without relapse, and shows promise for alopecia universalis through targeted miasmatic and constitutional remedies.

This study found that 90% of pediatric patients with alopecia areata had comorbidities, including allergic rhinitis and atopic dermatitis, with localized AA being associated with better treatment outcomes and fewer relapses compared to non-localized forms.

This review outlines the major health consequences of anabolic-androgenic steroid abuse, with a focus on sexual and reproductive issues, and suggests management prioritizes cessation and relapse prevention due to lack of robust randomized trials.

In this case report, a female patient with both psoriasis and lichen planus initially responded to acitretin and topical mometasone but experienced a relapse after stopping the treatment. The authors reported marked improvement within 3 months after switching to upadacitinib, aiming to guide clinical decision-making.

This review discusses the use of Janus kinase inhibitors for severe alopecia areata in Japan, noting their effectiveness in some patients but highlighting the need for new therapies due to non-responsiveness and relapse in others; it reports no new clinical results.

This case report described a Persian cat with psychogenic alopecia and secondary dermatitis linked to environmental stress, which improved with antihistamine therapy, diet changes, and owner interaction, but relapsed in a high cat population setting.

This case report describes a 33-year-old male with treatment-resistant psoriasis who experienced complete resolution of symptoms and hair regrowth after following an integrated Shodhana-Shamana chikitsa regimen, with no relapse noted at follow-up, suggesting its potential for sustainable Ekakustha management.

This case report observed that an integrated Shodhana-Shamana treatment protocol effectively managed treatment-resistant Ekakustha (plaque psoriasis), resulting in complete symptom resolution and no relapse at follow-up.

This review highlights that while pharmacotherapy, including biological agents, provides varying but often partial control of hidradenitis suppurativa depending on disease severity, significant challenges and high relapse rates persist, necessitating further research for more effective treatments.

This case study reports the successful use of abrocitinib for treating severe alopecia areata in a 14-year-old patient, demonstrating significant hair regrowth and suggesting the need for sustained JAK1 inhibition to prevent relapse.

This study examined 14 dogs with alopecia areata and found that oral ciclosporin was the most common treatment, with some dogs experiencing hair regrowth, though relapses were common when the medication was tapered or withdrawn.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

In this study, oral tofacitinib significantly reduced alopecia severity in pediatric patients with moderate-to-severe alopecia areata over 24 weeks, with 42.2% achieving complete or near-complete hair regrowth, although further research is needed on long-term safety and relapse rates.

This study of patients with moderate to severe alopecia areata in Morocco found that oral betamethasone mini-pulses yielded ≥50% hair regrowth in 62.5% of cases, improved quality of life scores, and were generally well-tolerated, though relapses and mild side effects were noted.

This review highlights the potential role of vitamin D and its analogs in managing alopecia areata, noting that vitamin D deficiency and altered receptor expression may be linked to disease severity and that supplementation could help reduce severity and relapse rates.

This case report describes a 28-year-old woman who developed alopecia areata following prolonged emotional stress, with improvement observed using Minoxidil and stress management, but relapse occurred after another stressful period.

This study discusses the role of Janus kinase inhibitors in treating severe alopecia areata, highlighting their potential to personalize treatment and improve patient quality of life, while addressing concerns about disease relapse after stopping treatment and the safety of long-term use.

In this study, intravenous corticosteroid pulse therapy for rapidly progressive alopecia areata showed that 74.5% of patients achieved a good response in the long-term, and a revised scoring system predicted relapse risk effectively in cases with preceding infectious symptoms.

This case report highlights an atypical presentation of favus in an immunocompetent adult, where a psoriasiform plaque over the 'bindi' area was successfully treated with systemic itraconazole, achieving complete resolution without relapse. Simple stains proved essential for diagnosis in this resource-limited setting.

In this case, ayurvedic medicines were reported to effectively manage a patient with alopecia areata, with fewer side effects and reduced relapse rates compared to conventional treatments.

In this study, a 40-year-old man with hair loss showed complete hair regrowth and no relapse 24 weeks after receiving umbilical cord mesenchymal stem cell and secretome injections, highlighting their potential for alopecia treatment, although further research involving larger populations is needed.